# Diagnostic Performances of Urine and Plasma 5-hydroxyindolacetic Acid (5HIAA) Values in Patients With Small-intestine Neuroendocrine Tumors

> **NCT02826928** · NA · COMPLETED · sponsor: **CHU de Reims** · enrollment: 116 (actual)

## Conditions studied

- Small-intestine Neuroendocrine Tumors (Carcinoid Tumors)

## Interventions

- **BIOLOGICAL:** blood sample withdrawn

## Key facts

- **NCT ID:** NCT02826928
- **Lead sponsor:** CHU de Reims
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-26
- **Primary completion:** 2020-02-28
- **Final completion:** 2022-06-03
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02826928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02826928, "Diagnostic Performances of Urine and Plasma 5-hydroxyindolacetic Acid (5HIAA) Values in Patients With Small-intestine Neuroendocrine Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02826928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*